Geron Corporation (NASDAQ:GERN)‘s stock had its “hold” rating restated by equities research analysts at Stifel Nicolaus in a note issued to investors on Friday. They currently have a $2.50 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 17.92% from the stock’s previous close.

Other analysts have also recently issued reports about the stock. BidaskClub cut shares of Geron Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Zacks Investment Research cut shares of Geron Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $3.75.

Shares of Geron Corporation (NASDAQ GERN) traded down $0.05 during trading on Friday, reaching $2.12. 935,088 shares of the company were exchanged, compared to its average volume of 1,275,479.

Geron Corporation (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Geron Corporation had a negative net margin of 2,992.67% and a negative return on equity of 25.14%. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.40 million. During the same period last year, the firm earned ($0.02) earnings per share. The company’s quarterly revenue was down 96.8% on a year-over-year basis. equities analysts forecast that Geron Corporation will post -0.17 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/11/04/stifel-nicolaus-reiterates-hold-rating-for-geron-corporation-gern.html.

Institutional investors and hedge funds have recently bought and sold shares of the stock. IHT Wealth Management LLC purchased a new position in Geron Corporation during the second quarter valued at $122,000. Russell Investments Group Ltd. purchased a new position in shares of Geron Corporation in the 2nd quarter worth $114,000. Parametric Portfolio Associates LLC grew its stake in shares of Geron Corporation by 59.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 47,976 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 17,877 shares in the last quarter. Tudor Investment Corp ET AL grew its stake in shares of Geron Corporation by 12.1% in the 1st quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 5,669 shares in the last quarter. Finally, Zacks Investment Management purchased a new position in shares of Geron Corporation in the 2nd quarter worth $148,000. 38.78% of the stock is owned by institutional investors.

About Geron Corporation

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with MarketBeat.com's FREE daily email newsletter.